Epilepsy Therapeutics Market Strategy Analysis And Trends To 2019
In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong> Size, Share, Global <strong>Trends</strong>, Company Profiles,<br />
Demand, Insights, <strong>Analysis</strong>, Research, Report, Opportunities, Segmentation<br />
and Forecast <strong>To</strong> <strong>2019</strong><br />
In 2012, the overall industry for epilepsy therapeutics in the major developed markets<br />
contributed for an approximate share of over $3.1 billion. Furthermore, this market is<br />
anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast<br />
period till <strong>2019</strong>.<br />
<strong>Epilepsy</strong> is described by recurring seizures as it is a set of long-term neurological disorders.<br />
When a group of neurons in brains or nerve cells send wrong signals, episodes of these seizures<br />
occur. Depending on the cause of the epilepsy, seizures may possibly be different from primary<br />
comprehensive seizures to partial seizures. Patients suffering from epilepsy act weirdly and<br />
grumble about strange sensations and emotions. People of all ages are being affected by epilepsy<br />
as it is the fourth most common disorder. Doctors prescribe drugs or antiepileptic medicines for<br />
the treatment of epilepsy. It depends on the age of the patient seriousness of the seizures and type<br />
of seizures to be treated<br />
Recent approvals of drugs coupled with novel technologies of action are some of the factors<br />
attributing to the industry growth of the market. The U.S region contributes to the major market<br />
share for over 55% for the total market. In addition, three new anti-epileptic drugs have been<br />
permitted in the aforementioned region since 2012. Fycompa, Trobalt and Aptiom are also<br />
projected to be launched over the coming years. Moreover, brivaracetam is likely to approve<br />
over the coming years. Factors such as improved safety and tolerability of fycoma and trobalt<br />
are also contributing significantly owing to the increased interest of prescribers over the past few<br />
years.<br />
Access Full Report: http://www.radiantinsights.com/research/epilepsy-therapeutics-inmajor-developed-markets-to-<strong>2019</strong>-new-aeds-with-novel-mechanisms-of-action-signal-ashift-in-treatment-patterns<br />
Constant uptake of anti-epileptic drugs of second and third generation is anticipated to attribute<br />
towards the revenues in these regions. Although, the market could experience the hindering<br />
impact of geriatric competition as a result of novel patent expiries in all the key industries<br />
especially for key branded drugs like Lamictal and Keppra.<br />
Key market players operating for epilepsy therapeutics in the major developed markets are<br />
Novartis AG, GlaxoSmithKine plc, Shire, Johnson & Johnson Pfizer, Sanofi S.A, Cephalon,<br />
Abbot Laboratories, Sunovion Pharmaceuticals, Shire and Valeant Pharamceutical International<br />
Inc.<br />
Table Of Content:<br />
Table of Contents 5
1.1 List of Tables 7<br />
1.2 List of Figures 8<br />
2 Introduction 9<br />
2.1 Disease Overview 9<br />
2.2 Epidemiology 9<br />
2.3 Symptoms 11<br />
2.4 Etiology 11<br />
2.5 Pathophysiology 12<br />
2.6 Co-morbidities/Complications 12<br />
2.7 Diagnosis 12<br />
2.8 Prognosis 13<br />
2.9 Treatment Efficacy 13<br />
2.10 Treatment Options 14<br />
2.10.1 Ion Channel Modulators 14<br />
2.10.2 GABA-ergic Facilitation 15<br />
2.10.3 Excitatory Amino Acid Inhibitors 15<br />
2.10.4 Synaptic Modulators 15<br />
2.11 Non-pharmacological Management 15<br />
2.11.1 Lobectomy and Lesionectomy 15<br />
2.11.2 Ketogenic Diet and Modified Atkins Diet 15<br />
2.11.3 Vagus Nerve Stimulation 16<br />
Browse All Reports of This Category @<br />
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare<br />
3 <strong>Epilepsy</strong> Therapeutic Landscape 17<br />
3.1 Overview 17<br />
3.2 Lyrica (pregabalin) 17<br />
3.3 Lamictal (lamotrigine) 18<br />
3.4 Keppra (levetiracetam) 19<br />
3.5 Zonegran (zonisamide) 21<br />
3.6 Vimpat (lacosamide) 22<br />
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 24<br />
3.8 Fycompa (perampanel) 24<br />
3.9 Trobalt/Potiga (ezogabine/retigabine) 25<br />
3.10 Banzel/Inovelon (rufinamide) 26<br />
3.11 Comparative Efficacy and Safety of <strong>Market</strong>ed Products 26<br />
4 Pipeline for <strong>Epilepsy</strong> <strong>Therapeutics</strong> 29<br />
4.1 Overall Pipeline 29<br />
4.2 Pipeline by Mechanism of Action 31<br />
4.3 Clinical Trials 32<br />
4.3.1 Failure Rate 32<br />
4.3.2 Patient Enrolment and Clinical Trial Size 34
4.3.3 Clinical Trial Duration 36<br />
4.4 Promising Pipeline Candidates 38<br />
4.4.1 Brivaracetam - UCB 38<br />
4.4.2 Ganaxolone - Marinus Pharmaceuticals 38<br />
5 <strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong> Forecast to <strong>2019</strong> 39<br />
5.1 Geographical <strong>Market</strong>s 39<br />
5.1.1 Major Developed <strong>Market</strong>s 39<br />
5.1.2 The US 40<br />
5.1.3 <strong>To</strong>p Five EU Countries 43<br />
5.1.4 Japan 46<br />
5.1.5 Canada 48<br />
5.2 Drivers and Barriers 50<br />
5.2.1 Drivers 50<br />
5.2.2 Barriers 50<br />
6 Deals and Strategic Consolidations 52<br />
6.1 Deals <strong>Analysis</strong> 52<br />
6.2 Research and Development Co-development Agreements 54<br />
6.3 Research and Development Licensing Agreements 55<br />
<strong>To</strong> Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/epilepsytherapeutics-in-major-developed-markets-to-<strong>2019</strong>-new-aeds-with-novel-mechanisms-ofaction-signal-a-shift-in-treatment-patterns#tabs-4<br />
7 Appendix 57<br />
7.1 Abbreviations 57<br />
7.2 References 58<br />
7.3 References for Heat Maps 62<br />
7.4 Pipeline Products by Phase 63<br />
7.4.1 Discovery 63<br />
7.4.2 Preclinical 63<br />
7.4.3 IND-filed and Phase 0 64<br />
7.4.4 Phase I 65<br />
7.4.5 Phase II 65<br />
7.4.6 Phase III 66<br />
7.4.7 Pre-registration 66<br />
7.5 <strong>Market</strong> Forecasting Data Tables to <strong>2019</strong> 67<br />
7.5.1 Major Developed <strong>Market</strong>s 67<br />
7.5.2 US 67<br />
7.5.3 UK 67<br />
7.5.4 France 68<br />
7.5.5 Germany 68<br />
7.5.6 Italy 68<br />
7.5.7 Spain 69
7.5.8 Japan 69<br />
7.5.9 Canada 69<br />
7.6 Research Methodology 70<br />
7.6.1 Coverage 70<br />
7.6.2 Secondary Research 70<br />
7.6.3 Primary Research 70<br />
7.6.4 Therapeutic Landscape 71<br />
7.6.5 Geographical Landscape 74<br />
7.6.6 Pipeline <strong>Analysis</strong> 74<br />
7.7 Expert Panel Validation 74<br />
7.8 Contact Us 74<br />
7.9 Disclaimer 74<br />
About Us<br />
Radiant Insights is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive<br />
collection of reports, covering over 40 key industries and a host of micro markets. In addition to<br />
over extensive database of reports, our experienced research coordinators also offer a host of<br />
Ancillary services such as, research partnerships/ tie-ups and customized research solutions.<br />
Media Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
Phone: 1-415-349-0054<br />
<strong>To</strong>ll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Website: Radiant Insights<br />
Visit Our Blog: radiantri.blogspot.com
Change language